Rapport Therapeutics (RAPP) Net Income towards Common Stockholders (2023 - 2026)

Rapport Therapeutics (RAPP) has reported Net Income towards Common Stockholders for 4 consecutive years, with -$19.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 17.48% year-over-year to -$19.9 million; the TTM figure through Mar 2026 stood at -$107.3 million (down 34.6% YoY), while the FY2025 annual figure was -$111.5 million, down 42.37% from the prior year.
• Net Income towards Common Stockholders improved to -$19.9 million in Q1 2026 per RAPP's latest filing, from -$33.8 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$6.4 million in Q2 2023 and bottomed at -$33.8 million in Q4 2025.
• Historically, Net Income towards Common Stockholders has averaged -$19.9 million across 4 years, with a median of -$19.9 million in 2024.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders slumped 182.65% — and 2026, when it gained 17.48%.
• Rapport Therapeutics' Net Income towards Common Stockholders stood at -$13.5 million in 2023, then sank by 47.79% to -$20.0 million in 2024, then tumbled by 68.98% to -$33.8 million in 2025, then surged by 41.19% to -$19.9 million in 2026.
• Business Quant data shows RAPP's Net Income towards Common Stockholders at -$19.9 million in Q1 2026, -$33.8 million in Q4 2025, and -$26.9 million in Q3 2025.